SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-000593
Filing Date
2024-05-06
Accepted
2024-05-06 16:07:34
Documents
63
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cldx-20240331x10q.htm   iXBRL 10-Q 1069533
2 EX-31.1 cldx-20240331xex31d1.htm EX-31.1 13475
3 EX-31.2 cldx-20240331xex31d2.htm EX-31.2 13334
4 EX-32.1 cldx-20240331xex32d1.htm EX-32.1 6653
  Complete submission text file 0001410578-24-000593.txt   5227772

Data Files

Seq Description Document Type Size
5 EX-101.SCH cldx-20240331.xsd EX-101.SCH 32153
6 EX-101.CAL cldx-20240331_cal.xml EX-101.CAL 39643
7 EX-101.DEF cldx-20240331_def.xml EX-101.DEF 137612
8 EX-101.LAB cldx-20240331_lab.xml EX-101.LAB 329505
9 EX-101.PRE cldx-20240331_pre.xml EX-101.PRE 236341
67 EXTRACTED XBRL INSTANCE DOCUMENT cldx-20240331x10q_htm.xml XML 974723
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 24917532
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)